Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: Breast Cancer|Metastatic Breast Cancer|Triple Negative Breast Cancer
Sponsor: University of Milano Bicocca
Collaborators: EISAI s.r.l.